108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
液体活检技术在肺癌中的应用：文献计量学研究与可视化分析
Authors Xu Y, Huang B, Zhu G, Chen N, Gao Y, Wu Z , Mo L, Liu L
Received 29 June 2025
Accepted for publication 15 September 2025
Published 23 September 2025 Volume 2025:17 Pages 2153—2168
DOI https://doi.org/10.2147/CMAR.S550357
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Yueqi Xu,1,2,* Biao Huang,2,* Guoshuang Zhu,1 Nidan Chen,2 Yao Gao,1,2 Zenan Wu,1 Lisha Mo,2 Liangji Liu2
1School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China; 2Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Liangji Liu, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China, Email llj6505@163.com Zenan Wu, School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China, Email a3265640@163.com
Background: Lung cancer is a major global health threat, and traditional treatments are hindered by tumor heterogeneity and drug resistance. Liquid biopsy technology offers new opportunities for precise diagnosis and treatment of lung cancer; however, its clinical application still presents challenges. Therefore, we aimed to elucidate the research progress and future trends of liquid biopsy technology through a bibliometric analysis.
Methods: Literature on liquid biopsy technology in lung cancer research spanning from 1990 to 2024 was retrieved from the Web of Science Core Collection. Various bibliometric tools were employed, including VOSviewer (1.6.20), Cite Space (6.2.R3), RStudio (utilizing the R package bibliometrix), and Scimago Graphica, to explore the current situation and research hotspots in this area. The research covered multiple aspects, including publication counts, contributions from different countries and institutions, journals involved, authorship, co-references, and keywords. By generating corresponding visualization maps, an attempt was made to forecast future development trends within this research field.
Results: We identified 363 articles published in 198 journals, authored by 2518 authors from 266 institutions across 54 countries/regions. The journal, country, institution, and author with the highest number of publications were Cancer, China, Harvard University, and ROLFO C. Over the past 34 years, research on the application of liquid biopsy technology in lung cancer have primarily focused on cancer diagnosis, biomarkers, and treatment monitoring.
Conclusion: Liquid biopsy technology is rapidly evolving in the field of lung cancer. Detecting biomarkers such as circulating tumor DNA, circulating tumor cells, and extracellular vesicles, facilitates early detection and monitoring of treatment response, reveals drug resistance mechanisms, and promotes personalized treatment. With the advancement of technology and international cooperation, liquid biopsy is expected to provide more accurate diagnosis and treatment for patients with lung cancer in the future.
Keywords: liquid biopsy technique, tumor, bibliometric tools, bibliometrics, citespace, VOSviewer
1School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China; 2Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Liangji Liu, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China, Email llj6505@163.com Zenan Wu, School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China, Email a3265640@163.com
Background: Lung cancer is a major global health threat, and traditional treatments are hindered by tumor heterogeneity and drug resistance. Liquid biopsy technology offers new opportunities for precise diagnosis and treatment of lung cancer; however, its clinical application still presents challenges. Therefore, we aimed to elucidate the research progress and future trends of liquid biopsy technology through a bibliometric analysis.
Methods: Literature on liquid biopsy technology in lung cancer research spanning from 1990 to 2024 was retrieved from the Web of Science Core Collection. Various bibliometric tools were employed, including VOSviewer (1.6.20), Cite Space (6.2.R3), RStudio (utilizing the R package bibliometrix), and Scimago Graphica, to explore the current situation and research hotspots in this area. The research covered multiple aspects, including publication counts, contributions from different countries and institutions, journals involved, authorship, co-references, and keywords. By generating corresponding visualization maps, an attempt was made to forecast future development trends within this research field.
Results: We identified 363 articles published in 198 journals, authored by 2518 authors from 266 institutions across 54 countries/regions. The journal, country, institution, and author with the highest number of publications were Cancer, China, Harvard University, and ROLFO C. Over the past 34 years, research on the application of liquid biopsy technology in lung cancer have primarily focused on cancer diagnosis, biomarkers, and treatment monitoring.
Conclusion: Liquid biopsy technology is rapidly evolving in the field of lung cancer. Detecting biomarkers such as circulating tumor DNA, circulating tumor cells, and extracellular vesicles, facilitates early detection and monitoring of treatment response, reveals drug resistance mechanisms, and promotes personalized treatment. With the advancement of technology and international cooperation, liquid biopsy is expected to provide more accurate diagnosis and treatment for patients with lung cancer in the future.
Keywords: liquid biopsy technique, tumor, bibliometric tools, bibliometrics, citespace, VOSviewer